Table 2.

Chemotherapy regimens.

Regimen	n	ORR (%)	DCR (%)	AE (n)	AE incidence (%)
< NSCLC >
Tri-weekly CBDCA + PTX	113	32.7	62.8	13	11.5
CBDCA + PEM	61	21.3	54.1	10	16.4
CBDCA + S-1	42	23.8	50.0	2	4.8
CBDCA + PTX + Bev	32	59.4	81.3	4	12.5
CDDP + PEM	26	38.5	57.7	3	11.5
DTX	26	11.5	34.6	9	34.6
CBDCA + nab-PTX	26	42.3	69.2	1	3.8
CBDCA + PEM + Bev	23	43.5	87.0	3	13.0
Weekly CBDCA + PTX	21	42.9	71.4	1	4.8
PEM	17	11.8	23.5	3	17.6
CDDP + DTX	15	60.0	80.0	2	13.3
S-1	13	0	38.5	2	15.4
VNR	12	8.3	33.3	3	25.0
CDDP + VNR	11	27.3	63.6	0	0
CBDCA + VP16	11	9.1	45.5	1	9.1
Others#	43	–	–	5	11.6
Total	492	29.3	58.7	62	12.6
< SCLC >
CBDCA + VP16	160	51.2	64.4	5	3.1
CDDP + VP16	34	52.9	70.6	2	5.9
CDDP + CPT11	10	50.0	80.0	0	0
CBDCA + CPT11	6	66.7	66.7	1	16.7
Others##	6	–	–	1	16.7
Total	216	51.4	65.7	9	4.2

AE acute exacerbation, AMR amrubicin, Bev bevacizumab, CBDCA carboplatin, CDDP cisplatin, CPT-11 irinotecan, DTX docetaxel, NDP nedaplatin, nab-PTX nanoparticle albumin-bound paclitaxel, NGT nogitecan, NSCLC non-small cell lung cancer, ORR objective response rate, PEM pemetrexed, PTX paclitaxel, SCLC small cell lung cancer, VNR vinorelbine; VP-16 etoposide.

^#'Others' includes regimens consisting of 10 cases or less, i.e. CDDP + S-1 (n = 9), CDDP + VP-16 (n = 4), CBDCA + DTX (n = 3), CBDCA + gemcitabine (GEM) (n = 3), CBDCA + VNR (n = 3), weekly CBDCA + PTX + Bev (n = 2), CBDCA + CPT-11 (n = 1), CBDCA + PTX + Bev (n = 1), CDDP + GEM (n = 2), CDDP + S-1 + Bev (n = 1), PTX (n = 5), Gefitinib (n = 3), GEM (n = 2), Nedaplatin (n = 1), Bev (n = 1), UFT (n = 1), and PEM + BEV (n = 1).

^##'Others' includes regimens consisting of five cases or less, i.e. AMR (n = 3), monthly CBDCA + PTX (n = 2), and VP-16 (n = 1).